Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Preclinical studies show bladder cancers, mesotheliomas respond to treatment with ADI-PEG 20

Scientists from academic institutions reported at the 2013 annual American Association for Cancer Research meeting, results from preclinical studies which showed that certain bladder cancers and mesotheliomas have metabolic changes and are more likely to respond to treatment with ADI-PEG 20 (pegylated arginine deiminase) if they are deficient in the enzyme, argininosuccinate synthetase.

18 Apr 2013

Study shows hsa-miR-146a overexpressed in most metastatic tumors

In order to kill, bladder cancer must metastasize, most commonly to the lung - what are the differences between bladder cancers that do and do not make this deadly transition? Research presented by the Director of the University of Colorado Cancer Center at the AACR Annual Meeting 2013 shows that one big difference is a little molecule known as hsa-miR-146a.

11 Apr 2013

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.

10 Apr 2013

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th).

8 Apr 2013

First patient dosed in second Phase 2 study with LiRIS for treatment of Interstitial Cystitis

TARIS Biomedical, a specialty pharmaceutical company developing innovative, targeted therapies to treat bladder diseases with high unmet medical need, announced today that it has dosed the first patient in its second Phase 2 clinical study with LiRIS, its novel product candidate, in patients with Interstitial Cystitis.

3 Apr 2013

Engineers develop prototype telerobotic platform for bladder cancer treatment

Although bladder cancer is the sixth most common form of cancer in the U.S. and the most expensive to treat, the basic method that doctors use to treat it hasn't changed much in more than 70 years.

3 Apr 2013

IGDRASOL to present updates on Cynviloq at AACR annual meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its development of Cynviloq (IG-001) at the annual meeting of the American Association for Cancer Research in Washington, DC (April 6th to 10th).

1 Apr 2013

Bladder cancer risk linked to genetic alterations

A new analysis has found that genetic alterations in a particular cellular pathway are linked with bladder cancer risk, recurrence, disease progression, and patient survival. Published early online in CANCER, a peer- reviewed journal of the American Cancer Society, the findings could help improve bladder cancer screening and treatment.

26 Mar 2013

Study investigates prognostic indicators for BCa patients treated with RC

A new study from Japan investigated various prognostic indicators, including clinico-pathological and pre-operative hematological factors to develop a novel prognostic factors-based risk stratification model for disease-specific survival in bladder cancer patients treated with radical cystectomy.

19 Mar 2013

Study on neoadjuvant cisplatin-based chemotherapy presented at 28th Annual EAU Congress

At the 28th Annual EAU Congress currently ongoing in Milan until Tuesday, W. Tan and colleagues presented their study on neoadjuvant cisplatin-based chemotherapy which showed that epigenetic changes are potential key drivers in the development of chemo resistance in bladder cancer.

18 Mar 2013

Smoking increases risk of developing serious forms of urothelial cancer

Smoking significantly increases individuals’ risk of developing serious forms of urothelial carcinoma and a higher likelihood of dying from the disease, particularly for women. That is the conclusion of a recent study published in BJU International. While the biological mechanisms underlying this gender difference are unknown, the findings indicate that clinicians and society in general should focus on smoking prevention and cessation to safeguard against deadly cancers of the bladder, ureters, and renal pelvis, especially in females.

14 Mar 2013

DSMB recommends discontinuation of Aeterna Zentaris’ perifosine Phase 3 study for MM

Aeterna Zentaris Inc. today announced that an independent Data Safety Monitoring Board has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.

12 Mar 2013

New regeneration approach could be used for people with bladder issues

A new approach to bladder regeneration is capitalizing on the potential of two distinct cell populations harvested from a patient's healthy bone marrow, a new study reports.

19 Feb 2013

MicroRNAs hold promise as markers for bladder cancer prognosis

Researchers have found that microRNAs can be useful prognostic biomarkers for individuals with urothelial carcinoma.

18 Feb 2013

Bladder reconstruction rate after cystectomy varies

The use of bladder orthotopic reconstruction after cystectomy for cancer is uncommon in England and varies significantly among patient groups, report researchers.

11 Feb 2013

Microscopic hematuria poor indicator for renal, bladder malignancy

The presence of microscopic levels of blood in the urine is unreliable as an indicator for renal or bladder cancer, report researchers.

30 Jan 2013

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

28 Jan 2013

Bladder cancer risk associated with childbearing factors

The risk for bladder cancer in women may decline with increased parity and older age at first birth, researchers report.

21 Jan 2013

SPARC protein acts much like ibuprofen to heal tissues inflamed by tumors

Cancer researchers are increasingly aware that in addition to genetic mutations in a cancer itself, characteristics of the surrounding tissue can promote or suppress tumor growth. One of these important tissue characteristics is inflammation - most cancers prosper in and attach to inflamed tissue and so many cancers have developed ways to create it.

19 Jan 2013

Scientists identify new mechanism for schistosomiasis-bladder cancer connection

About 200 million people across 75 of the poorest countries in the world are now infected by the blood parasite Schistosoma haematobium (S. haematobium). The infection causes severe urogenital disease, but also causes bladder cancer in a number of patients and why this occurs is not clear.

17 Jan 2013

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Preclinical studies show bladder cancers, mesotheliomas respond to treatment with ADI-PEG 20

Study shows hsa-miR-146a overexpressed in most metastatic tumors

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

First patient dosed in second Phase 2 study with LiRIS for treatment of Interstitial Cystitis

Engineers develop prototype telerobotic platform for bladder cancer treatment

IGDRASOL to present updates on Cynviloq at AACR annual meeting

Bladder cancer risk linked to genetic alterations

Study investigates prognostic indicators for BCa patients treated with RC

Study on neoadjuvant cisplatin-based chemotherapy presented at 28th Annual EAU Congress

Smoking increases risk of developing serious forms of urothelial cancer

DSMB recommends discontinuation of Aeterna Zentaris’ perifosine Phase 3 study for MM

New regeneration approach could be used for people with bladder issues

MicroRNAs hold promise as markers for bladder cancer prognosis

Bladder reconstruction rate after cystectomy varies

Microscopic hematuria poor indicator for renal, bladder malignancy

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Bladder cancer risk associated with childbearing factors

SPARC protein acts much like ibuprofen to heal tissues inflamed by tumors

Scientists identify new mechanism for schistosomiasis-bladder cancer connection

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in